Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
PBF Energy prices USD 500 million 0% exchangeable notes due 2032

PBF Energy prices USD 500 million 0% exchangeable notes due 2032

ReutersReuters2026/09/15 03:02
  • PBF Energy priced a private offering of USD 500 million 0% exchangeable notes due 2032.
  • Issuance expected to close Sept. 17.
  • Net proceeds estimated at about USD 485 million, rising to about USD 533.6 million with a USD 50 million upsized option.
  • Most proceeds earmarked to repay or redeem outstanding 7.875% senior unsecured notes due 2030.
  • Initial exchange price set at about USD 96.8 a share, a 37.5% premium to the prior close.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PBF Energy Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609142302PR_NEWS_USPR_____NY47888) on September 15, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage